Mostrar el registro sencillo del ítem
| dc.contributor.author | Llorca, Javier | |
| dc.contributor.author | Ferraz-Amaro, Iván | |
| dc.contributor.author | Moreno-Martínez, María-José | |
| dc.contributor.author | Plaza, Zulema | |
| dc.contributor.author | Sánchez-Alonso, Fernando | |
| dc.contributor.author | Moreno-Ramos, Manuel-José | |
| dc.contributor.author | García-Gómez, Carmen | |
| dc.contributor.author | Castaneda, Santos | |
| dc.contributor.author | González-Juanatey, Carlos | |
| dc.contributor.author | González-Gay, Miguel-Ángel | |
| dc.date.accessioned | 2026-04-20T09:43:43Z | |
| dc.date.available | 2026-04-20T09:43:43Z | |
| dc.date.issued | 2026-04 | |
| dc.identifier.citation | Llorca J, Ferraz-Amaro I, Moreno-Martínez MJ, Plaza Z, Sánchez-Alonso F, Moreno-Ramos MJ, et al. Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort. Seminars in Arthritis and Rheumatism. abril de 2026;77:152923. doi:10.1016/j.semarthrit.2026.152923 | |
| dc.identifier.issn | 0049-0172 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/25919 | |
| dc.description.abstract | Objective: To identify predictors of cardiovascular (CV) events in psoriatic arthritis (PsA) patients from the CARdiovascular in RheuMAtology (CARMA) project during 10 years of prospective follow-up. Methods: Between July 2010 and January 2012, 725 PsA patients were enrolled from 67 Spanish hospitals. Analyses focused on 682 patients without prior CV events at baseline. At 10-year follow-up, CV event occurrence, patient-years, and linearized event rates were evaluated. Cox regression analyses were performed, both crude and adjusted for the PREVENT-CVD score. Results: Over 6397 patient-years, 85 patients (12.46%) experienced CV events, yielding a rate of 1.33 per 100 patient-years. Patients with CV events were older (67.1 +/- 11.1 vs. 56.7 +/- 11.8 years, p < 0.001), more often male (68.2% vs. 51.9%, p = 0.005), and had higher frequencies of hypertension (60.0% vs. 21.8%, p < 0.001), diabetes (18.8% vs. 6.0%, p = 0.001), and dyslipidemia (56.5% vs. 29.8%, p < 0.001). They also showed greater abdominal perimeter and body mass index (p < 0.05 for both). After adjusting for PREVENT-CVD, the highest tertile of DAS28-ESR remained a significant predictor of CV events (HR 1.79; 95%CI: 1.03-3.14; p = 0.04). Urate in the highest tertile was also independently associated in the crude model (HR 1.88; 95%CI: 1.11-3.20; p = 0.02). When stratified (<6.5, 6.5-8.9, and >= 9.0 mg/dl), urate >= 9.0 mg/dl was also associated with increased risk of CV events in the adjusted model (HR 3.50; 95%CI: 1.10-11.2; p = 0.02). While HAQ score in the third tertile was associated with increased CV risk in the crude analysis (HR 1.70; p = 0.04), this association did not persist after adjustment. Conclusions: Disease activity and elevated urate levels independently predict CV events in PsA, highlighting their value as markers of CV risk beyond traditional factors captured by the PREVENT-CVD score. | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER | |
| dc.rights | Atribución/Reconocimiento 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/deed.es | * |
| dc.title | Disease activity and hyperuricemia predict the development of cardiovascular events in patients with Psoriatic Arthritis: results of the 10-year prospective evaluation in the CARMA cohort | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 41548490 | |
| dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S0049017226000120 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1016/j.semarthrit.2026.152923 | |
| dc.journal.title | Seminars in Arthritis and Rheumatism | |
| dc.identifier.essn | 1532-866X |